Global Viral Vector Manufacturing Market - 2023-2030

Global Viral Vector Manufacturing Market - 2023-2030

Global Viral Vector Manufacturing Market reached US$ 0.9 billion in 2022 and is expected to reach US$3.8 billion by 2030 growing with a CAGR of 20.3% during the forecast period 2023-2030. The global viral vector manufacturing market has witnessed significant growth in recent years. The increasing focus on next-generation viral vectors is driving up demand for viral vector manufacturing market trends.

The viral vector manufacturing market has witnessed significant growth and innovation in recent years. Viral vector manufacturing involves the production of viral vectors, such as adeno-associated viruses (AAV), lentiviruses, and adenoviruses, through various manufacturing processes. These processes include upstream production, downstream purification, and quality control. Overall, the viral vector manufacturing market is poised for continued expansion as gene therapies and vaccines become more prominent in the treatment and prevention of various diseases.

The global viral vector manufacturing market is driven by the factors such as the increasing adoption of gene and cell therapies, the increasing number of clinical trials in this field, advancements in gene therapies, and technological advancements in viral vector manufacturing.

Market Dynamics

Increasing Adoption of Gene and Cell Therapies Drives the Growth of the Viral Vector Manufacturing Market

The prevalence of genetic disorders and chronic diseases, such as cancer, is increasing globally. Gene and cell therapies offer promising solutions for these conditions by addressing the underlying genetic abnormalities or enhancing the immune response against cancer cells. The rising patient population and unmet medical needs drive the demand for viral vectors used in gene and cell therapies.

Viral vector manufacturing has witnessed significant advancements, enabling more efficient and scalable production. Innovations in vector design, production platforms, and purification techniques have improved the quality, safety, and yield of viral vectors. These technological advancements facilitate the commercialization of gene and cell therapies and contribute to market growth.

For instance, in April 2023, Yposkesi, SK Pharmteco’s clinical and commercial viral vector manufacturing arm for cell and gene therapies, announced the launch of LentiSure, an optimized Lentiviral (LV) Vector manufacturing platform for increasing lentivirus production efficiency and robustness. Lentivirus or LV vectors are used to produce cell-based immuno-oncology therapies. Their robustness as a gene delivery system is vital in determining the success of any cell-based cancer treatment.

Increasing Demand for Viral Vectors in Research Also Drives the Growth of the Viral Vector Manufacturing Market

As the demand for viral vectors in research increases, there will be a corresponding and increasing need for higher production volumes to meet the growing requirements. Viral vector manufacturers will scale up their production capabilities to satisfy the market demand, leading to increased market share. The viral vectors are also used in clinical trials to develop cell and gene therapies for disease treatments.

For instance, on June 9, 2023, American Gene Technologies, a clinical-stage biotechnology company is launching a new company, Addimmune, to continue to develop gene and cell therapy technologies to cure HIV. Addimmune will focus solely on advancing an HIV cure, building upon more than a decade of work by AGT that led to a successful Phase 1 HIV gene and cell therapy clinical trial.

The continuous advancements in research techniques, such as gene editing and gene therapy, have expanded the applications of viral vectors in research. Viral vectors are commonly employed as delivery vehicles for these advanced technologies, enabling precise genome editing and gene delivery. As researchers adopt and refine these techniques, the demand for viral vectors to support such research is expected to rise.

The Short Shelf-Life of Viral Vectors Will Hamper the Growth of the Market

Viral vectors require specific storage conditions, such as ultra-low temperatures or cryopreservation, to maintain their integrity and efficacy. These storage requirements can be costly and logistically challenging, especially for products that need to be transported to remote or resource-limited areas. The need for specialized storage and distribution infrastructure adds to the overall costs and complexity of the supply chain.

The short shelf-life of viral vectors restricts their availability in the market. Manufacturers must carefully manage inventory and production schedules to ensure that products do not expire before reaching patients. This limitation can lead to supply shortages, delays in treatment, and difficulties in meeting patient demand.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global viral vector manufacturing market. The COVID-19 pandemic has prompted a shift in research focus towards the development of vaccines and therapies targeting the SARS-CoV-2 virus. Many companies and research institutions have redirected their resources and expertise towards developing viral vector-based COVID-19 vaccines and treatments, potentially affecting the growth of the overall viral vector manufacturing market.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global viral vector manufacturing market. Regulatory frameworks and approvals for viral vector-based therapies can be influenced by geopolitical factors. The conflict leads to changes in regulatory policies and requirements, affecting the approval timelines and market access for viral vector-based products. These regulatory uncertainties can have implications for the global viral vector manufacturing market.

Segment Analysis

The global viral vector manufacturing market is segmented based on type, disease, application, end-user, and region.

Adenoviral Vectors from the Type Segment Accounts for 37.7% of the Viral Vector Manufacturing Market Share

Adenoviral vectors are derived from adenoviruses, which are non-enveloped viruses with a large genome capable of accommodating sizable transgenes. Adenoviral vectors exhibit high transduction efficiency, meaning they can efficiently deliver therapeutic genes or antigens into target cells. This efficient transduction is due to their ability to infect a broad range of dividing and non-dividing cells, making them suitable for various applications in gene therapy and vaccine delivery.

Adenoviral vectors can stimulate robust immune responses, making them valuable in vaccine development. They can induce both humoral (antibody-mediated) and cellular (T-cell-mediated) immune responses against the encoded antigens. This immunogenicity is advantageous for developing vaccines against infectious diseases and cancer immunotherapies.

For instance, in October 2022, TEHRAN (Tasnim), the Chinese city of Shanghai started administering inhalable COVID-19 booster vaccinations. The vaccine is an adenovirus type-5 vector-based COVID-19 vaccine administered via oral inhalation.

Geographical Analysis

North America Accounted for Approximately 39.8% of the Market Share Owing to the Presence of Major Players and Advanced Healthcare Infrastructure

North America is home to numerous leading biotechnology and pharmaceutical companies that actively engage in viral vector manufacturing. These companies have established expertise in gene therapy and vaccine development and possess robust manufacturing capabilities. Their investments in research and development, manufacturing infrastructure, and clinical trials contribute to the market's growth and dominance in the region.

For instance, in May 2023, AGC Biologics announced the launch of its BravoAAV and ProntoLVV viral vector platforms. Leveraging three decades of Lentiviral vector (LVV) and Adeno-Associated Viral vector (AAV) development, manufacturing, and analytical experience, AGC Biologics’ new platforms offer fast, efficient, and reproducible clinical and commercial GMP production and release.

North America boasts a well-developed healthcare infrastructure with advanced facilities and expertise in genetic medicine. The presence of renowned academic institutions, research centers, and healthcare systems fosters collaborations and knowledge exchange among industry stakeholders. This infrastructure supports the development, manufacturing, and commercialization of viral vectors for gene therapies and vaccines.

Competitive Landscape

The major global players in the viral vector manufacturing market include Sanofi SA, Thermo Fisher Scientific Inc., Cobra Biologics Ltd, Lonza Group Ltd, Merck & Co., Oxford BioMedica, CGT Catapult, UniQure NV, FUJIFILM Diosynth Biotechnologies, and Spark Therapeutics Inc.

Why Purchase the Report?
• To visualize the global viral vector manufacturing market segmentation based on type, disease, application, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of viral vector manufacturing market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global viral vector manufacturing market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies